
|Videos|August 26, 2021
Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
2
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
3
Q&A: Making Plant-Based Eating Practical in Pharmacy-Led Cardiometabolic Care
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5



























